Oncolytic Orf virus licenses NK cells via cDC1 to activate innate and adaptive antitumor mechanisms and extends survival in a murine model of late-stage ovarian cancer.
Jacob P van VlotenKathy MatuszewskaMark A A MinowJessica A MinottLisa A SantryMadison PereiraAshley A StegelmeierThomas M McAuslandElaine M KlafuricKhalil KarimiJoseph ColasantiD Grant McFaddenJames J PetrikByram W BridleSarah K WoottonPublished in: Journal for immunotherapy of cancer (2022)
The data herein support the translational potential of OrfV as an NK stimulating immunotherapeutic for the treatment of advanced-stage ovarian cancer.